Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ABBV-368 |
Trade Name | |
Synonyms | ABBV368|ABBV 368 |
Drug Descriptions |
ABBV-368 is an activating monoclonal antibody to the T-cell receptor, TNFRSF4 (OX40, CD134) (NCI Drug Dictionary). |
DrugClasses | OX40 Antibody 14 |
CAS Registry Number | 2230138-89-1 |
NCIT ID | C161864 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABBV-368 | ABBV-368 | 0 | 2 |
ABBV-368 + ABBV-927 | ABBV-368 ABBV-927 | 0 | 1 |
ABBV-368 + ABBV-927 + Budigalimab | ABBV-368 ABBV-927 Budigalimab | 0 | 1 |
ABBV-368 + ABBV-927 + Carboplatin | ABBV-368 ABBV-927 Carboplatin | 0 | 1 |
ABBV-368 + ABBV-927 + Nab-paclitaxel | ABBV-368 ABBV-927 Nab-paclitaxel | 0 | 1 |
ABBV-368 + Budigalimab + IMO-2125 + Nab-paclitaxel | ABBV-368 Budigalimab IMO-2125 Nab-paclitaxel | 0 | 1 |
ABBV-368 + IMO-2125 | ABBV-368 IMO-2125 | 0 | 1 |
ABBV-368 + IMO-2125 + Nab-paclitaxel | ABBV-368 IMO-2125 Nab-paclitaxel | 0 | 1 |
ABBV-368 + Nivolumab | ABBV-368 Nivolumab | 0 | 1 |